somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
== History == One of the first LITs was constructed in 1969, by Dierdre A. Church, who bent linear quadrupoles into closed circle and racetrack geometries and demonstrated storage of 3He+ and H+ ions for several minutes. Earlier, Drees and Paul described a circular quadrupole. However, it was used to produce and confine a plasma, not to store ions. In 1989, Prestage, Dick, and Malecki described that ions could be trapped in the linear quadrupole trap system to enhance ion-molecule reactions, thus it can be used to study spectroscopy of stored ions.
Activated protein C–protein C inhibitor (APC-PCI) is a complex of activated protein C (APC) and protein C inhibitor (PCI). It has been measured in coagulation testing to evaluate coagulation, thrombosis, and other cardiovascular complications. It is a marker of thrombin generation and indicates hypercoagulability or presence of thrombosis. Activated Protein C is a vitamin K-dependent serine protease that cleaves and inactivates Factor Va and Factor VIIIa, thus acting as an anticoagulant. Protein C Inhibitor is a 54-kilodalton glycoprotein of the serpin superfamily. Like other serpins, upon cleavage by PC, PCI undergoes a dramatic conformational rearrangement resulting in a stable covalent bond between the two proteins. The resulting PC-PCI protein dimer lacks enzyme activity and is permanently inactivated, an example of suicide inhibition. Formation of this complex is one of the major means of regulation of protein C activity, so that pro-coagulation and anticoagulant activities are kept in balance.
Owing to the presence of d-shell, uranium (as well as many other actinides) forms organometallic compounds, such as UIII(C5H5)3 and UIV(C5H5)4. Neptunium has valence states from 3 to 7, which can be simultaneously observed in solutions. The most stable state in solution is +5, but the valence +4 is preferred in solid neptunium compounds. Neptunium metal is very reactive. Ions of neptunium are prone to hydrolysis and formation of coordination compounds. Plutonium also exhibits valence states between 3 and 7 inclusive, and thus is chemically similar to neptunium and uranium. It is highly reactive, and quickly forms an oxide film in air. Plutonium reacts with hydrogen even at temperatures as low as 25–50 °C; it also easily forms halides and intermetallic compounds. Hydrolysis reactions of plutonium ions of different oxidation states are quite diverse. Plutonium(V) can enter polymerization reactions. The largest chemical diversity among actinides is observed in americium, which can have valence between 2 and 6. Divalent americium is obtained only in dry compounds and non-aqueous solutions (acetonitrile). Oxidation states +3, +5 and +6 are typical for aqueous solutions, but also in the solid state. Tetravalent americium forms stable solid compounds (dioxide, fluoride and hydroxide) as well as complexes in aqueous solutions. It was reported that in alkaline solution americium can be oxidized to the heptavalent state, but these data proved erroneous. The most stable valence of americium is 3 in aqueous solution and 3 or 4 in solid compounds.
=== A10BX Other blood glucose lowering drugs, excluding insulins === A10BX01 Guar gum A10BX02 Repaglinide A10BX03 Nateglinide A10BX05 Pramlintide A10BX06 Benfluorex A10BX08 Mitiglinide A10BX15 Imeglimin A10BX16 Tirzepatide A10BX17 Carfloglitazar A10BX18 Dorzagliatin
Sources: en.wikipedia.org
Askari had shaken the South African government's confidence in its ability to retain the military advantage indefinitely in Angola. Heavier and more sophisticated weapons were being used, the rate of casualties had increased, and the air superiority that had accounted for many of the SADF's previous successes was diminishing. Nor was Botha and his cabinet certain of continued political and diplomatic support from the US, which had chosen to abstain rather than exercise its veto with regard to UN Security Council Resolution 546. The Reagan administration perceived that both Angola and South Africa had grown weary of the war and were more susceptible to pressure for a ceasefire and mutual disengagement. American diplomats offered to mediate peace talks accordingly, and on 13 February South African and Angolan officials met for the first time in Lusaka. Three days later, South Africa announced that it would withdraw its expeditionary forces from Cunene Province by the end of March, provided the Angolans agreed to prevent PLAN from taking advantage of the situation to infiltrate South West Africa. The Angolan government pledged to restrain PLAN and MK, and to prohibit any movement of Cuban troops southward towards the border. These respective commitments were formalised as the Lusaka Accords. FAPLA and the SADF agreed to set up a Joint Monitoring Commission (JMC) to police the disengagement. Under the JMC, joint South African and Angolan patrols were carried out along six hundred kilometres of the border.
== Cap snatching and transcription in influenza == Cap snatching is best described in influenza viruses, especially influenza A. In Orthomyxoviridae, the viral family of influenza, the RdRp is divided into three subunits: PA, PB1 and PB2. PB1 first binds the 5' end of the viral RNA (vRNA), activating PB2 and causing the 3' end of the vRNA to form a double-stranded zone with the 5' end. The PB2 proceeds to bind cellular mRNA at the N7-methyl guanosine (m7G) capped 5' end. The PA subunit subsequently cleaves the sequence 10-13 nucleotides from the cap structure via endonuclease activity at the N terminus. The exact cleavage location is dependent both on the distance between the PB2 and the PA of the RdRp (around 50 angstroms or 10-13 nucleotides) and also the sequence of the mRNA. Then, the PB1 subunit, which contains the polymerase activity, initially adds on two new nucleotides. The cap snatched primer moves through the product exit tunnel in the PB1 domain to serve as the primer for transcription. The vRNA 3'-UCGUUUU nucleotides are not bound to the polymerase but rather are free for complementary binding with the capped RNA primer to confer stability. Transcription then begins with G or C residue on the 3' end of the capped primer. Finally, the PB1 subunit completes chain elongation in the canonical 5' to 3' direction, releasing the cap, but keeping the 5' end bound. The viral 3' poly-A tail is added at the end of transcription by polymerase stuttering from the steric hindrance of the vRNA loop.
Chang, Ken Jeong, Moon Molson, Theresa Navarro Gen Art Film Festival Winner, Best Feature: Half-Life - 2008 Mannheim-Heidelberg International Film Festival Nominee, Main Award of Mannheim-Heidelberg: Half-Life - 2008 Philadelphia Asian American Film Festival Nominee, Festival Prize: Advantageous (short) - 2012 Philadelphia Film Festival Nominee, Jury Award for Best Short: Advantageous (short) - 2012 San Diego Asian Film Festival Nominee, Jury Award for Best Narrative Short: Advantageous (short) - 2012 San Diego Comic-Con Independent Film Festival Nominee, CCI:IFF Award for Best Science Fiction/Fantasy Film: Advantageous (short) - 2012 Tokyo International Film Festival Nominee, Tokyo Grand Prix: Half-Life - 2008 Urbanworld Film Festival Nominee, Jury Prize for Best Short: Advantageous - 2012
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.